"Empagliflozin significantly reduced CI-AKI incidence in PCI patients by enhancing renal function markers, including eGFR and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback